Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 3/20 | 0.53 |
| ▸ | GRN | P28799 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19618762 | 0.81 | TSHR (0.51) | SLC6A4SLC6A3SLC6A2TSHRKMO | |
| SCHEMBL904487 | 0.80 | HTT (0.51) | TSHRSRD5A2 | |
| SCHEMBL634228 | 0.79 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2TSHRKMO | |
| SCHEMBL8305858 | 0.79 | TSHR (0.57) | SLC6A4SLC6A3SLC6A2TSHRKMO | |
| SCHEMBL2290370 | 0.78 | SLC6A2 (0.51) | SLC6A4SLC6A3SLC6A2HPGD | |
| SCHEMBL7229416 | 0.77 | TPMT (0.48) | GRNSORT1 | |
| SCHEMBL2294689 | 0.76 | CES2 (0.51) | SLC6A3SLC6A2 | |
| SCHEMBL15309758 | 0.76 | SLC6A4 (0.52) | SLC6A4SLC6A3SLC6A2TSHRKMO | |
| SCHEMBL760302 | 0.76 | TSHR (0.57) | SLC6A4SLC6A3SLC6A2TSHRKMO | |
| SCHEMBL23792281 | 0.76 | SLC6A4 (0.52) | SLC6A4SLC6A3SLC6A2TSHRKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-03-27 | — | — | US | disclosed |
| US-8541409-B2 | Carbamoyloxy arylalkanoyl arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-09-24 | — | — | US | disclosed |
| EP-2155736-B1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO LTD (KR) | 2011-12-21 | — | — | EP | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| EP-2155736-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK Holdings Co., Ltd. (KR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008140198-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO., LTD. (KR) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, OPRD1, OPRL1 | SLC6A4 641/4885SLC6A3 1294/4885SLC6A2 1189/4885 |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, CNR2, CNR1 | SLC6A4 700/4885SLC6A3 1180/4885SLC6A2 1147/4885 |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | HTR5A, OPRL1, HDAC3 | SLC6A4 727/4885SLC6A3 1265/4885SLC6A2 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.